Leerink Partnrs Estimates Cencora's Q4 Earnings (NYSE:COR)

Key Points

• Leerink Partners has reduced its Q4 2025 earnings per share estimate for Cencora from $3.85 to $3.81, while the consensus estimate for the full-year earnings stands at $15.37 per share.
• Multiple analysts have raised their price targets for Cencora, with UBS Group increasing theirs to $335.00 and Robert W. Baird to $350.00, reflecting a generally positive outlook despite the earnings downgrade.
• Cencora has reported a quarterly earnings per share of $4.00, exceeding analyst estimates, alongside a revenue increase of 8.7% year-over-year to $80.66 billion.

Cencora, Inc. (NYSE:COR - Free Report) - Stock analysts at Leerink Partnrs dropped their Q4 2025 earnings estimates for shares of Cencora in a research note issued on Wednesday, August 6th. Leerink Partnrs analyst M. Cherny now anticipates that the company will earn $3.81 per share for the quarter, down from their prior forecast of $3.85. The consensus estimate for Cencora's current full-year earnings is $15.37 per share.

Cencora (NYSE:COR - Get Free Report) last posted its quarterly earnings data on Wednesday, August 6th. The company reported $4.00 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $3.79 by $0.21. Cencora had a return on equity of 267.36% and a net margin of 0.60%. The company had revenue of $80.66 billion during the quarter, compared to analysts' expectations of $80.34 billion. During the same quarter in the previous year, the business earned $3.34 EPS. Cencora's revenue was up 8.7% compared to the same quarter last year.

Several other equities research analysts have also recently weighed in on the company. Jefferies Financial Group upped their target price on Cencora from $275.00 to $300.00 and gave the stock a "hold" rating in a report on Monday, June 30th. Morgan Stanley set a $330.00 target price on Cencora and gave the stock an "equal weight" rating in a report on Wednesday, July 16th. Citigroup upped their target price on Cencora from $330.00 to $355.00 and gave the stock a "buy" rating in a report on Thursday, May 8th. Robert W. Baird upped their target price on Cencora from $314.00 to $350.00 and gave the stock an "outperform" rating in a report on Thursday, May 8th. Finally, Wells Fargo & Company upped their target price on Cencora from $337.00 to $354.00 and gave the stock an "overweight" rating in a report on Wednesday. Three investment analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average target price of $311.25.

Cencora Trading Up 0.5%

COR traded up $1.33 during trading hours on Monday, reaching $290.48. 1,353,575 shares of the company's stock traded hands, compared to its average volume of 1,573,708. The firm has a 50-day moving average price of $292.44 and a 200 day moving average price of $278.38. Cencora has a 52-week low of $218.65 and a 52-week high of $309.35. The company has a quick ratio of 0.53, a current ratio of 0.90 and a debt-to-equity ratio of 3.64. The firm has a market capitalization of $56.30 billion, a PE ratio of 29.88, a PEG ratio of 1.38 and a beta of 0.58.

Institutional Trading of Cencora

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Atlantic Edge Private Wealth Management LLC boosted its position in Cencora by 70.0% during the second quarter. Atlantic Edge Private Wealth Management LLC now owns 85 shares of the company's stock worth $25,000 after purchasing an additional 35 shares in the last quarter. Cornerstone Planning Group LLC lifted its position in shares of Cencora by 106.7% in the first quarter. Cornerstone Planning Group LLC now owns 93 shares of the company's stock valued at $26,000 after acquiring an additional 48 shares in the last quarter. Hoey Investments Inc. purchased a new position in shares of Cencora in the first quarter valued at approximately $28,000. Costello Asset Management INC purchased a new position in shares of Cencora in the first quarter valued at approximately $28,000. Finally, Banque Transatlantique SA purchased a new position in shares of Cencora in the fourth quarter valued at approximately $29,000. 97.52% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Cencora

In related news, Chairman Steven H. Collis sold 14,579 shares of the firm's stock in a transaction dated Tuesday, June 24th. The stock was sold at an average price of $292.62, for a total transaction of $4,266,106.98. Following the sale, the chairman directly owned 311,913 shares of the company's stock, valued at $91,271,982.06. This trade represents a 4.47% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Robert P. Mauch sold 4,968 shares of the firm's stock in a transaction dated Friday, July 18th. The stock was sold at an average price of $294.11, for a total value of $1,461,138.48. Following the sale, the chief executive officer directly owned 42,351 shares in the company, valued at approximately $12,455,852.61. This trade represents a 10.50% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 34,125 shares of company stock worth $9,993,789 over the last three months. Corporate insiders own 10.80% of the company's stock.

Cencora Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 3rd. Stockholders of record on Friday, August 15th will be issued a $0.55 dividend. The ex-dividend date of this dividend is Friday, August 15th. This represents a $2.20 dividend on an annualized basis and a dividend yield of 0.8%. Cencora's dividend payout ratio is currently 22.63%.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.